Reactogenicity of tetanus, diphtheria, 5-component acellular pertussis vaccine administered as a sixth consecutive acellular pertussis vaccine dose to adolescents

Pediatric Infectious Disease Journal

Volumn 29, Issue 12, 2010, Pages 1067-1071

  Liese, Johannes G ^a   Rieber, Nikolaus ^b   Malzer, Thomas ^c   Ocak, Marion ^d   Johnson, David R ^e   Decker, Michael D ^e,f  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Conreso GmbH ^*  (Germany)

^d MD Research   (Germany)

^e SANOFI PASTEUR   (France)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acellular pertussis vaccine; adolescents; reactogenicity; Tdap

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE; UNCLASSIFIED DRUG; WHOLE CELL PERTUSSIS VACCINE;

ADOLESCENT; ADVERSE OUTCOME; ARM CIRCUMFERENCE; ARTICLE; AXILLARY PAIN; CHILD; CLINICAL ASSESSMENT; DIPHTHERIA; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LIMB SWELLING; LYMPH NODE PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; PAIN; PERTUSSIS; PHASE 4 CLINICAL TRIAL; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SIDE EFFECT; TETANUS; TREATMENT RESPONSE; VACCINATION; VERTIGO; VOMITING;

ADOLESCENT; CHILD; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; EDEMA; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMANS; IMMUNIZATION, SECONDARY; MALE; PAIN; SKIN DISEASES;

EID: 78049496454     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181ea5866     Document Type: Article

References (19)

1. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics. 2006;117:965-978.
2. Centers for Disease Control and Prevention. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-7):1-25.
3. Pichichero ME, Edwards KM, Anderson EL, et al. Safety and immunoge-nicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics. 2000;105:e11.
4. Englund JA, Decker MD, Edwards KM, et al. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study. Pediatrics. 1994; 93:37-43.
5. Gustafsson L, Hessel L, Storsaeter J, et al. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics. 2006;118:978-984.
6. Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunoge-nicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15 to 20month-old children. Pediatrics. 1997;100:772-788.
7. Liese JG, Stojanov S, Zink TH, et al; Munich Vaccine Study Group. Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Pediatr Infect Dis J. 2001;20:981-988.
8. Pichichero ME, DeTora LM, Johnson DR. An adolescent and adult formulation combined tetanus, diphtheria and five-component pertussis vaccine. Expert Rev Vaccines. 2006;5:175-187.
9. Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA. 2005;293:3003-3011.
10. Pichichero ME, Casey JR, Francis AB, et al. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules. Clin Pediatr (Phila). 2006;45:613-620.
11. Zepp F, Knuf M, Habermehl P, et al. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr. 2006; 149:603-610.
12. Knuf M, Schmitt HJ, Wolter J, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr. 2008;152:655-660.
13. Centers for Disease Control and Prevention. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-4):1-51.
14. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-3):1-34.
15. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep. 2006;55(RR-17):1-37.
16. Liese JG, Meschievitz CK, Harzer E, et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J. 1997;16:1038-1044.
17. Post-marketing evaluation of reactions following receipt of recommended adolescent pertussis vaccine. Available at: http://www.clinicaltrials.gov/ ct2/show/NCT00304265. Accessed May 8, 2010.
18. Robert Koch-Institut. Empfehlungen der Staendigen Impfkommission (STIKO). Epidemiologisches Bulletin. 2002;30:257-272.
19. Galanis E, King AS, Varughese P, et al. Changing epidemiology and emerging risk groups for pertussis. CMAJ. 2006;174:451-452.